News
-
-
-
COMMUNIQUÉ DE PRESSE
Xlife Sciences AG Publishes 2023 ESG Report: A Continued Commitment to Sustainable Innovation
Xlife Sciences AG releases 2023 ESG Report, showcasing commitment to sustainable innovation. Report aligns with GRI Standards and emphasizes environmental, social, and governance performance -
-
-
COMMUNIQUÉ DE PRESSE
Xlife Sciences AG Announces the Intended Listing of VERAXA Biotech AG on the NASDAQ Stock Exchange in the 2025 Fiscal Year
Xlife Sciences AG announces the intended listing of VERAXA Biotech AG on the NASDAQ Stock Exchange in the 2025 fiscal year, aiming to advance novel cancer therapies and create value for shareholders -
-
-
-